Best response (confirmed at 6 weeks) at the end of 8 cycles
| . | N = 55 . |
|---|---|
| n (%) . | |
| Overall response (at least partial response) | 19 (34.5) |
| Complete response | 0 |
| Near-complete response | 1 (1.8) |
| Partial response | 18 (32.7) |
| Clinical benefit rate (at least minimal response) | 29 (52.7) |
| Minimal response | 10 (18.2) |
| Stable disease | 20 (36.4) |
| Progressive disease | 3 (5.5) |
| Unknown* | 3 (5.5) |
| Very good partial response† | 3 (5.5) |
| . | N = 55 . |
|---|---|
| n (%) . | |
| Overall response (at least partial response) | 19 (34.5) |
| Complete response | 0 |
| Near-complete response | 1 (1.8) |
| Partial response | 18 (32.7) |
| Clinical benefit rate (at least minimal response) | 29 (52.7) |
| Minimal response | 10 (18.2) |
| Stable disease | 20 (36.4) |
| Progressive disease | 3 (5.5) |
| Unknown* | 3 (5.5) |
| Very good partial response† | 3 (5.5) |